Repeating l- and d-chiral configurations
determine
polylactide (PLA) stereochemistry, which affects its thermal and physicochemical
properties, including degradation profiles. Clinically, degradation
of implanted PLA biomaterials promotes prolonged inflammation and
excessive fibrosis, but the role of PLA stereochemistry is unclear.
Additionally, although PLA of varied stereochemistries causes differential
immune responses in vivo, this observation has yet to be effectively
modeled in vitro. A bioenergetic model was applied to study immune
cellular responses to PLA containing >99% l-lactide (PLLA),
>99% d-lactide (PDLA), and a 50/50 melt-blend of PLLA
and
PDLA (stereocomplex PLA). Stereocomplex PLA breakdown products increased
IL-1β, TNF-α, and IL-6 protein levels but not MCP-1. Expression
of these proinflammatory cytokines is mechanistically driven by increases
in glycolysis in primary macrophages. In contrast, PLLA and PDLA degradation
products selectively increase MCP-1 protein expression. Although both
oxidative phosphorylation and glycolysis are increased with PDLA,
only oxidative phosphorylation is increased with PLLA. For each biomaterial,
glycolytic inhibition reduces proinflammatory cytokines and markedly
increases anti-inflammatory (IL-10) protein levels; differential metabolic
changes in fibroblasts were observed. These findings provide mechanistic
explanations for the diverse immune responses to PLA of different
stereochemistries and underscore the pivotal role of immunometabolism
in the biocompatibility of biomaterials applied in medicine.